1.0
2 Sept 2024
Current employee, more than 5 years
Barcelona
Recommend
CEO approval
Business outlook
Pros
Interactions with FDA, EMA and local agencies at the Regulatory Department
Cons
In the Clinical Development Dpt, employees without elemental medical and scientific knowledge, lack of GCP rules during the trial execution, many problems with many "interpretations" of study protocol and data leading to very poor results